Bevacizumab Alone Effective for Recurrent Glioblastoma
the Cancer Therapy Advisor take:
Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma, according to a recent study published in Medical Oncology.
Researchers led by Ilhan Hacibekiroglu of Trakya University in Turkey observed 22 patients with glioblastoma and two patients with World Health Organization III glioma who had been previously treated with temozolomide with radiotherapy and received 10mg/kg bevacizumab intravenously every two weeks until disease progression.
The researchers found that the performance status of 17 patients (70.8 percent) was improved with the bevacizumab regimen. Upon univariate analysis, performance status following bevacizumab therapy was found to be a significant predictor of both progression-free survival (PFS) and overall survival (OS).
In addition, overall response rate was 20.8 percent, with median OS at 6.4 months. Six-month PFS was 37.5 percent and median PFS was 4.1 months.
Single-agent bevacizumab is an effective and safe treatment for patients with recurrent glioblastoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed